Hathal Haddad, Head of Interventional Radiotherapy Unit at University Hospital Tübingen, shared a post on LinkedIn:
“16 Days Until Brachytherapy Awareness Day 2026.
HDR-Brachytherapy Monotherapy for Prostate Cancer.
High Precision. Curative Intent. Organ Preservation.
For men with localized prostate cancer, HDR brachytherapy monotherapy represents one of the most precise forms of radiation treatment available. By placing temporary catheters directly into the prostate under image guidance, HDR brachytherapy delivers an ablative radiation dose to the tumor while minimizing exposure to the bladder, rectum, and urethra.
Common HDR monotherapy schedules include:
- 2 × 13.5 Gy (1–2 weeks apart)
- 3 × 11.5 Gy (completed over 2–3 weeks)
These fractionation schedules are supported by prospective clinical studies and international guidelines for appropriately selected patients.
Why HDR brachytherapy?
- Submillimeter treatment precision
- Excellent organ sparing
- Outstanding long-term biochemical control
- Low rates of severe urinary and rectal toxicity
- Preservation of urinary, bowel, and sexual quality of life
- Outpatient treatment with only a few treatment sessions
Ideal candidates generally include patients with:
- Localized prostate cancer (cT1–T2)
- Low- and favorable intermediate-risk disease
- Good urinary function
- Appropriate prostate anatomy for implantation
HDR brachytherapy combines precision, efficiency, and excellent long-term outcomes, making it one of the most effective curative treatment options for selected men with localized prostate cancer.
High precision today. Better outcomes tomorrow. Better care. Better outcomes. Better quality of life.
17 July 2026 – Brachytherapy Awareness Day.”
Other articles about Brachytherapy on OncoDaily.